ArticleProceedings of the National Academy of Sciences of the United States of America2021
Growth hormone-releasing hormone agonists ameliorate chronic kidney disease-induced heart failure with preserved ejection fraction.
Open access · greenAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- ATP Synthase Inhibitory Factor-1 Deficiency Attenuates Doxorubicin Cardiotoxicity by Preserving Mitochondrial Structure and Function.International journal of molecular sciences · 2026Article
- A novel mouse model for cardiovascular-kidney-metabolic syndrome: Bridging metabolic, renal and cardiac dysfunction.Molecular metabolism · 2026Article
- Therapeutic potential of growth hormone-releasing hormone analogues in cardiovascular and cerebrovascular diseases: mechanisms and preclinical evidence.Frontiers in pharmacology · 2026Review
- When in doubt, pig it out: a versatile translational platform to study CKD, HFpEF, and CKM syndrome.American journal of physiology. Heart and circulatory physiology · 2025Review
- Evaluation of the Therapeutic Potential of Synthetic Growth Hormone-Releasing Hormone Antagonist MIA-690 as a Cognitive Modulator in a Mouse Model of Gulf War Illness.International journal of molecular sciences · 2025Article
- Effects of GHRH and its analogues on the Vascular System.Reviews in endocrine & metabolic disorders · 2025Review
- The development of growth hormone-releasing hormone analogs: Therapeutic advances in cancer, regenerative medicine, and metabolic disorders.Reviews in endocrine & metabolic disorders · 2025Review
- Growth hormone-releasing hormone signaling and manifestations within the cardiovascular system.Reviews in endocrine & metabolic disorders · 2025Review
- Growth hormone-releasing hormone and its analogues in health and disease.Nature reviews. Endocrinology · 2025Review
- A minimally invasive swine model of chronic kidney disease-associated heart failure.American journal of physiology. Heart and circulatory physiology · 2025Article
- A Nomogram to Predict the Risk for MACCE within 1 Year after Discharge of Patients with NVAF and HFpEF: A Multicenter Retrospective Study.Reviews in cardiovascular medicine · 2023Article
- Efficacy of a growth hormone-releasing hormone agonist in a murine model of cardiometabolic heart failure with preserved ejection fraction.American journal of physiology. Heart and circulatory physiology · 2023Article
- Synthetic growth hormone-releasing hormone agonist ameliorates the myocardial pathophysiology characteristic of heart failure with preserved ejection fraction.Cardiovascular research · 2023Article
- Agonist of growth hormone-releasing hormone improves the disease features of spinal muscular atrophy mice.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Still finding ways to augment the existing management of acute and chronic kidney diseases with targeted gene and cell therapies: Opportunities and hurdles.Frontiers in medicine · 2023Review
- Allogeneic Cell Combination Therapy Ameliorates Chronic Kidney Disease-Induced Heart Failure with Preserved Ejection Fraction.Stem cells translational medicine · 2022Article
- Telmisartan ameliorates cardiac fibrosis and diastolic function in cardiorenal heart failure with preserved ejection fraction.Experimental biology and medicine (Maywood, N.J.) · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Angela C RiegerInterdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL 33136.ORCID https://orcid.org/0000-0002-8625-0881
Luiza L BagnoInterdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL 33136.ORCID https://orcid.org/0000-0002-3112-4079
Alessandro SalernoInterdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL 33136.ORCID https://orcid.org/0000-0002-7688-5904
Victoria FloreaInterdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL 33136.ORCID https://orcid.org/0000-0001-6550-8524
Jose RodriguezInterdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL 33136.ORCID https://orcid.org/0000-0001-8426-0018
Marcos RosadoInterdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL 33136.ORCID https://orcid.org/0000-0002-0994-5110
Darren TurnerInterdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL 33136.ORCID https://orcid.org/0000-0002-4641-989X
Raul A DulceInterdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL 33136.ORCID https://orcid.org/0000-0003-1354-0180
Lauro M TakeuchiInterdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL 33136.ORCID https://orcid.org/0000-0002-4517-9548
Rosemeire M Kanashiro-TakeuchiInterdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL 33136.ORCID https://orcid.org/0000-0002-7305-9172
Peter BuchwaldDepartment of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL 33136.ORCID https://orcid.org/0000-0003-2732-8180
Amarylis C B A WanschelInterdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL 33136.ORCID https://orcid.org/0000-0002-5603-7983
Wayne BalkanInterdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL 33136.ORCID https://orcid.org/0000-0003-0405-0489
Ivonne H SchulmanInterdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL 33136.ORCID https://orcid.org/0000-0002-2814-2321
Andrew V SchallyDiabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136; andrew.schally@va.gov jhare@med.miami.edu.ORCID https://orcid.org/0000-0003-1273-6747
Joshua M HareInterdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL 33136; andrew.schally@va.gov jhare@med.miami.edu.ORCID https://orcid.org/0000-0002-7751-5032
University of Miami · US
Funding
ROLE OF Rac AND REACTIVE OXYGEN SPECIES IN KAPOSI'S SARCOMA VIRAL ONCOGENESISR01CA136387 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SHEMBADE, NOULA DATTU · 2010 to 2024
$7.1MCardioprotective Effect of Growth Hormone Releasing HormoneR01HL107110 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI HARE, JOSHUA M · 2011 to 2020
$5.9MCell Based Therapy for Non-Ischemic Dilated CardiomyopathyUM1HL113460 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI HARE, JOSHUA M · 2012 to 2018
$4.3MMesenchymal stem cell therapy for endothelial dysfunction in diabetesR01HL134558 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI HARE, JOSHUA M · 2016 to 2020
$3.2MNCI NIH HHS R01 CA136387NHLBI NIH HHS HHSN268201600012CNHLBI NIH HHS R01 HL107110NHLBI NIH HHS R01 HL134558NHLBI NIH HHS UM1 HL113460
Abstract
Therapies for heart failure with preserved ejection fraction (HFpEF) are lacking. Growth hormone-releasing hormone agonists (GHRH-As) have salutary effects in ischemic and nonischemic heart failure animal models. Accordingly, we hypothesized that GHRH-A treatment ameliorates chronic kidney disease (CKD)-induced HFpEF in a large-animal model. Female Yorkshire pigs (
Indexed as
AnimalsBlood Urea NitrogenCalciumCardiotonic AgentsConnectinCreatinineDisease Models, AnimalFemaleGene Expression RegulationGrowth Hormone-Releasing HormoneHeart FailureMyocytes, CardiacNatriuretic Peptide, BrainNephrectomyPeptide FragmentsProtein IsoformsCalciumCardiotonic AgentsConnectinCreatinineGrowth Hormone-Releasing HormoneNatriuretic Peptide, BrainN-Me-Tyr1,D-Ala2,Asn8,Arg29-NHCH3-JI-38Peptide Fragmentspro-brain natriuretic peptide (1-76)Protein IsoformsSermorelincardiorenal syndromechronic kidney diseaseheart failure with preserved ejection fractionlarge animal model
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.